[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [HEALTH]

11 clusters · 57 sources · 67 days · First seen · Last updated

Lenacapavir HIV prevention rollout and efficacy

Overview

Lenacapavir, a long-acting injectable medication for HIV pre-exposure prophylaxis (PrEP), has demonstrated high efficacy in clinical trials. The drug, which requires only two doses per year, is administered via subcutaneous injection to improve adherence compared to traditional daily oral regimens. Clinical trials PURPOSE 1 and PURPOSE 2 yielded results so significant that an independent monitoring committee recommended stopping the randomized phases early. Following its rollout in June 2026, the drug has seen significant demand in South Africa. As of September 7, 2026, the Department of Health reported that 55,123 individuals have been initiated on the treatment across approximately 360 public health facilities in 24 districts. In Latin America, Mexico’s sanitary regulatory agency, Cofepris, has authorized lenacapavir for HIV prevention following a scientific review of its quality, safety, and efficacy. This authorization aligns with the Pan American Health Organization (PAHO) agreement with Gilead Sciences to provide a coordinated procurement pathway through PAHO’s Regional Revolving Funds, covering 14 countries including Argentina, Brazil, Chile, Colombia, and Mexico. This decision follows 2025 recommendations from the World Health Organization regarding the use of biannual injectable lenacapavir as an additional PrEP option. In Africa, expansion efforts continue despite logistical hurdles. While Mozambique reports high uptake, Nigeria is experiencing supply shortages in several pilot states, including Benue, Kwara, Gombe, and Cross River. The National Agency for the Control of AIDS (NACA) attributed these stock-outs to funding and logistics challenges, though officials in Lagos report sufficient doses alongside low uptake among eligible residents. Meanwhile, in Ghana, the Ghana AIDS Commission continues to promote PrEP in tablet form due to limited injectable availability. Deployment is currently underway in South Africa, Kenya, Zambia, Nigeria, and Eswatini.

Entities

lenacapavir · Gilead Sciences · World Health Organization · Pan American Health Organization · Cofepris

Claims

What the coverage asserts, and how many sources carry each claim.

Coverage disagrees

Sources make claims that cannot both be true. CLSTR reports the disagreement; it does not decide who is right.

  • "Dr Reddy's Laboratories signed a royalty-free, non-exclusive voluntary licensing agreement with Gilead Sciences for once-yearly lenacapavir." www.news18.com

    vs

    "The once-yearly version of lenacapavir is currently in Phase 3 clinical trials and has not yet received regulatory approval." www.news18.com

    One claim asserts a licensing agreement exists for a once-yearly version of lenacapavir, while the other states the once-yearly version has not yet received regulatory approval.

Timeline

  1. [HEALTH] 2 sources
    Lenacapavir injectable offers new breakthrough in HIV prevention

    Lenacapavir, a twice-yearly injectable HIV prevention drug, shows high efficacy in trials. While deployment begins in parts of Africa, concerns persist regarding global access and cost.

  2. [HEALTH] 3 sources
    Cofepris approves Lenacapavir for HIV prevention in Mexico

    Mexico's Cofepris has approved Lenacapavir, a long-acting HIV prevention medication (PrEP) administered via subcutaneous injection just twice a year.

  3. [HEALTH] 3 sources
    Nigeria faces Lenacapavir shortages as HIV prevention demand rises

    Rising demand for the twice-yearly HIV prevention injection Lenacapavir has caused supply shortages in several Nigerian pilot states, including Benue and Kwara.

  4. [HEALTH] 20 sources
    Mexico authorizes lenacapavir for semiannual HIV prevention

    Mexico has authorized lenacapavir, a twice-yearly subcutaneous injection for HIV prevention (PrEP). PAHO also announced new access routes for the medication across 14 Latin American and Caribbean nations.

  5. [HEALTH] 3 sources
    HIV testing expands in Paraguay as Oruro reports rising cases

    Paraguay has tripled its annual HIV testing and gained access to the injectable preventative drug lenacapavir, while Oruro, Bolivia, reports a rise in HIV cases during the first half of 2026.

  6. [HEALTH] 10 sources
    PAHO and Gilead expand lenacapavir access in Latin America

    PAHO and Gilead Sciences have partnered to provide access to the long-acting HIV prevention drug lenacapavir to 14 Latin American and Caribbean countries via regional revolving funds.

  7. [HEALTH] 3 sources
    South Africa reports 55,000 initiations of new HIV prevention injection

    Over 55,000 people in South Africa have started using Lenacapavir, a new twice-yearly injectable HIV prevention medication, following its public sector rollout earlier this year.

  8. [HEALTH] 6 sources
    HIV prevention efforts expand in Mozambique and Ghana via PrEP

    Mozambique and Ghana are expanding HIV prevention efforts through the use of Pre-Exposure Prophylaxis (PrEP), utilizing both injectable lenacapavir and oral tablets to reduce infection risks.

  9. [HEALTH] 2 sources
    Lenacapavir HIV prevention injection expands access in Gauteng and India

    Gauteng is expanding access to Lenacapavir, a long-acting HIV prevention injection, amid high demand, while India explores the drug as a tool to combat rising HIV infection rates.

  10. [HEALTH] 5 sources
    Lenacapavir shows high efficacy in HIV prevention clinical trials

    The HIV prevention drug lenacapavir has shown unprecedented efficacy in clinical trials, offering a twice-yearly injection that improves adherence compared to daily oral PrEP regimens.

  11. [HEALTH] 2 sources
    Kenya rolls out long‑acting injectable HIV prevention Lenacapavir

    Kenya launches lenacapavir injectable HIV prevention, reducing doses to twice a year, while research shows broadly neutralising antibodies can extend viral control in a subset of patients.

Sources

adomonline.com · aimnews.org · aljama.co.za · altonivel.com.mx · am.com.mx · archynewsy.com · bizcommunity.com · blink102.com.br · cbc.bb · croniosv.com · dailyreport.ng · diarioestrategia.cl · diarioevolucion.com.mx · diarioimagen.net · diariolibre.com · ebnewsdaily.co.za · eenergetica.com.ar · elheraldopy.com · exclusivaspuebla.com.mx · fatopaulista.com.br · journaldeguinee.com · kpbs.org · ksfr.org · lapatria.bo · laprensa.mx · larepublica.ec · lopezdoriga.com · lucesdelsiglo.com.mx · massinformacion.com.mx · myjoyonline.com · mznews.co.mz · news18.com · noticias.mmo.co.mz · nouvelles-du-monde.com · nprinternedition.org · nuevolaredo.tv · observatoriog.bol.uol.com.br · ocio.farodevigo.es · parrotnewspaper.com · plataformanoticias.mx · plazadearmas.com.mx · psi.org · punchng.com · saludiario.com · sapo.pt · sciencedaily.com · sdpnoticias.com · sitedaserra.com.br

This summary has been updated 7 times: see revision history